Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).
We have launched a public consultation on the proposed adoption of the new EQ-5D-5L value set which will help us to make more accurate assessments of how treatments improve health-related quality of life.
NICE has implemented new measures to evaluate the cost-effectiveness of medicines, following a policy change that aims to give patients improved access to treatments.
People who have had a heart attack, stroke, or serious circulation problem in their legs, and who also carry excess weight, can now be offered a weekly injection to help protect them from a further life-threatening event, NICE has said.
NICE-recommended healthtech found the cause of Peter’s stroke. Read his story and discover how our guidance is helping life-changing innovations reach the patients who need them.
Hear from Ammaarah as she explains the remarkable impact hybrid closed loop technology has had on her life and how its successful rollout is the model we want to replicate.
Learn how the MHRA and NICE are getting medicines to patients 3 to 6 months sooner by delivering same time decisions on licensing and value.
Sophie Cooper, senior scientific adviser in NICE’s science policy team, explains the importance of the recently published EQ-5D-5L value set and how it has the potential to help us decide if new treatments offer good value for money for the NHS.
